BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 20495832)

  • 1. Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis.
    Botrel TE; Clark OA; Clark L; Paladini L; Faleiros E; Pegoretti B
    Support Care Cancer; 2011 Jun; 19(6):823-32. PubMed ID: 20495832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis.
    Piechotta V; Adams A; Haque M; Scheckel B; Kreuzberger N; Monsef I; Jordan K; Kuhr K; Skoetz N
    Cochrane Database Syst Rev; 2021 Nov; 11(11):CD012775. PubMed ID: 34784425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
    Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
    Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic review and meta-analysis of intravenous palonosetron in the prevention of chemotherapy-induced nausea and vomiting in adults.
    Likun Z; Xiang J; Yi B; Xin D; Tao ZL
    Oncologist; 2011; 16(2):207-16. PubMed ID: 21282670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron.
    Eisenberg P; Figueroa-Vadillo J; Zamora R; Charu V; Hajdenberg J; Cartmell A; Macciocchi A; Grunberg S;
    Cancer; 2003 Dec; 98(11):2473-82. PubMed ID: 14635083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Palonosetron: in the prevention of nausea and vomiting.
    Yang LP; Scott LJ
    Drugs; 2009 Nov; 69(16):2257-78. PubMed ID: 19852528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.
    Gralla R; Lichinitser M; Van Der Vegt S; Sleeboom H; Mezger J; Peschel C; Tonini G; Labianca R; Macciocchi A; Aapro M
    Ann Oncol; 2003 Oct; 14(10):1570-7. PubMed ID: 14504060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Palonosetron versus other 5-HT(3) receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with cancer on chemotherapy in a hospital outpatient setting.
    Balu S; Buchner D; Craver C; Gayle J
    Clin Ther; 2011 Apr; 33(4):443-55. PubMed ID: 21635990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy and safety of palonosetron with the first 5-HT3 receptor antagonists for the chemotherapy-induced nausea and vomiting: a meta-analysis.
    Jin Y; Sun W; Gu D; Yang J; Xu Z; Chen J
    Eur J Cancer Care (Engl); 2013 Jan; 22(1):41-50. PubMed ID: 22519361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Palonosetron: an evidence-based choice in prevention of nausea and vomiting induced by moderately emetogenic chemotherapy.
    Celio L; Agustoni F; Testa I; Dotti K; de Braud F
    Tumori; 2012; 98(3):279-86. PubMed ID: 22825501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis of randomized controlled trials.
    Popovic M; Warr DG; Deangelis C; Tsao M; Chan KK; Poon M; Yip C; Pulenzas N; Lam H; Zhang L; Chow E
    Support Care Cancer; 2014 Jun; 22(6):1685-97. PubMed ID: 24590374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Netupitant/Palonosetron: A Review in Chemotherapy-Induced Nausea and Vomiting.
    Shirley M
    Drugs; 2021 Jul; 81(11):1331-1342. PubMed ID: 34292534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
    Rubenstein EB
    Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Palonosetron.
    Siddiqui MA; Scott LJ
    Drugs; 2004; 64(10):1125-32; discussion 1133-4. PubMed ID: 15139789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serotonin receptor antagonists for highly emetogenic chemotherapy in adults.
    Billio A; Morello E; Clarke MJ
    Cochrane Database Syst Rev; 2010 Jan; (1):CD006272. PubMed ID: 20091591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Palonosetron: a second-generation 5-hydroxytryptamine receptor antagonist.
    Navari RM
    Future Oncol; 2006 Oct; 2(5):591-602. PubMed ID: 17026451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double-blind, noninferiority phase 3 trial.
    Raftopoulos H; Cooper W; O'Boyle E; Gabrail N; Boccia R; Gralla RJ
    Support Care Cancer; 2015 Mar; 23(3):723-32. PubMed ID: 25179689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase III open-label study to assess safety and efficacy of palonosetron for preventing chemotherapy-induced nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapy.
    Aogi K; Sakai H; Yoshizawa H; Masuda N; Katakami N; Yanagita Y; Inoue K; Kuranami M; Mizutani M; Masuda N
    Support Care Cancer; 2012 Jul; 20(7):1507-14. PubMed ID: 21808994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Palonosetron for the treatment of chemotherapy-induced nausea and vomiting.
    Navari RM
    Expert Opin Pharmacother; 2014 Dec; 15(17):2599-608. PubMed ID: 25323946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Palonosetron for prevention of delayed chemotherapy-induced nausea and vomiting in pediatric patients: a meta-analysis.
    Yamaguchi A; Saito Y; Takekuma Y; Sugawara M
    Support Care Cancer; 2023 Dec; 32(1):58. PubMed ID: 38145979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.